Extrawell Pharmaceutical Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 March 2024. The group expects to record a loss in the range between HKD 160 million and HKD 165 million, as compared to a profit for the year ended 31 March 2023. Such turnaround from profit to loss was primarily attributable to a non-cash item, resulted from the fair value change (loss) of the financial assets at fair value through profit or loss i.e. the Group's investments in convertible bonds, while a fair value change (gain) of the same non-cash item was recorded in the corresponding period last year.